To conclude, we have described two novel compound heterozygous variants of LPL in patients with type I hyperlipoproteinemia, showing that all these variants are pathogenic by disrupting LPL mass and the enzymatic activity of LPL. The gene discussed is LPL; the disease is familial chylomicronemia syndrome.